Fmr LLC Astria Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 6,054,561 shares of ATXS stock, worth $71.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,054,561

Previous 4,319,157 40.18%

Holding current value

$71.1 Million

Previous $60.8 Million 9.34%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$8.83 - $13.51 $15.3 Million - $23.4 Million	1,735,404 Added 40.18%	6,054,561 $55.1 Million
Q1 2024 May 13, 2024	SELL	$6.99 - $16.69 $3.38 Million - $8.08 Million	-483,868 Reduced 10.07%	4,319,157 $60.8 Million
Q4 2023 Feb 13, 2024	BUY	$4.42 - $8.06 $9.89 Million - $18 Million	2,237,973 Added 87.25%	4,803,025 $36.9 Million
Q3 2023 Nov 13, 2023	SELL	$6.89 - $9.86 $2.74 Million - $3.92 Million	-397,241 Reduced 13.41%	2,565,052 $19.1 Million
Q2 2023 Aug 11, 2023	SELL	$8.33 - $13.72 $2.13 Million - $3.51 Million	-255,685 Reduced 7.95%	2,962,293 $24.7 Million
Q1 2023 May 11, 2023	SELL	$11.2 - $15.79 $1.5 Million - $2.12 Million	-134,326 Reduced 4.01%	3,217,978 $42.8 Million
Q4 2022 Feb 13, 2023	BUY	$7.44 - $14.89 $22.1 Million - $44.3 Million	2,974,859 Added 788.16%	3,352,304 $49.9 Million
Q2 2022 Aug 12, 2022	BUY	$2.46 - $6.96 $57,960 - $163,984	23,561 Added 6.66%	377,445 $1.13 Million
Q1 2022 May 13, 2022	BUY	$3.92 - $7.1 $1.39 Million - $2.51 Million	353,884 New	353,884 $2.38 Million

Others Institutions Holding ATXS

# of Institutions

102

Shares Held

49.4M

Call Options Held

27.6K

Put Options Held

29.7K

View Full List

About Astria Therapeutics, Inc.

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $178M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

More about ATXS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account